Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy
Sign Up to like & getrecommendations! Published in 2019 at "Journal of NeuroVirology"
DOI: 10.1007/s13365-019-00793-4
Abstract: Natalizumab is effective against relapsing-remitting multiple sclerosis (MS) but increases the risk of progressive multifocal leukoencephalopathy (PML), which is caused by the activation of the JCV polyomavirus. SF2/ASF (splicing factor2/alternative splicing factor) is a potent… read more here.
Keywords: natalizumab treated; progressive multifocal; multifocal leukoencephalopathy; splicing factor2 ... See more keywords